Tharimmune, Inc. 8-K

What Happened
Tharimmune, Inc. (THAR) announced the appointment of Angela Dominy Radkowski, age 37, as Chief Operating Officer effective February 5, 2026, and that CEO Mark Wendland was elected Chairman of the Board at a February 5, 2026 special board meeting. The company also disclosed it regained compliance with Nasdaq Listing Rule 5605(b)(1) following the election of two independent directors at its January 30, 2026 shareholder meeting; the filing states Nasdaq notified the company that compliance was regained (the notice is dated February 2, 2025 in the filing).

Key Details

• COO hire: Angela Dominy Radkowski appointed effective February 5, 2026; prior roles at DRW Holdings and Citadel; B.S. in Business Administration from The Ohio State University.
• Compensation: Base salary $300,000/year; target annual cash bonus $100,000 (Board-determined and prorated for 2026); eligible for equity awards.
• Severance/termination: At-will employment; if terminated without cause or she resigns for “good reason,” she would receive 12 months of base salary (subject to release and other conditions).
• Board changes and committees (effective Feb 5, 2026): Mark Wendland elected Chair. Audit Committee — Gary Stetz (Chair), Clay Kahler, Jill E. Sommers. Compensation Committee — Gary Stetz (Chair), Clay Kahler, Jill E. Sommers. Nominating & Corporate Governance — Gary Stetz, Clay Kahler (Chair), Jill E. Sommers. Press release issued Feb 6, 2026.

Why It Matters
The hiring of a COO signals a strengthening of Tharimmune’s operational leadership and could affect execution of company initiatives; the package includes salary, bonus eligibility, equity opportunities and a potential 12-month severance exposure. Elevating the CEO to Board Chair and settling committee memberships clarifies governance roles. Regaining Nasdaq compliance removes a listing-related risk tied to board independence, which can improve investor confidence in corporate governance.